Sign In
Buy CDTX
$221.38
+0 (+0%)
At Close: Apr 07, 2026
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Moleculin Biotech (MBRX
Analysts Are Bullish on These Healthcare Stocks: Vericel (VCEL), Immunomedics (IMMU)
05:28pm, Thursday, 02'nd Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vericel (VCEL) and Immunomedics (IMMU) with bullish
Analysts Are Bullish on These Healthcare Stocks: Vericel (VCEL), Immunomedics (IMMU)
05:28pm, Thursday, 02'nd Apr 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vericel (
VCEL
–
Research Report
) and Immunomedics (
IMMU
–
Research Report
) with bullish sentime
Invitae (NVTA) Gets a Buy Rating from Oppenheimer
01:17am, Thursday, 02'nd Apr 2020
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Invitae (NVTA) yesterday and set a price target of $25.00. The company's shares closed last
Invitae (NVTA) Gets a Buy Rating from Oppenheimer
01:17am, Thursday, 02'nd Apr 2020
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Invitae (NVTA – Research Report) yesterday and set a price target
Analysts Are Bullish on Top Healthcare Stocks: Vascular Biogenics (VBLT), Marinus (MRNS)
10:29pm, Thursday, 19'th Mar 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vascular Biogenics (VBLT) and Marinus (MRNS) with bullish
Analysts Are Bullish on Top Healthcare Stocks: Vascular Biogenics (VBLT), Marinus (MRNS)
10:29pm, Thursday, 19'th Mar 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vascular Biogenics
Oppenheimer Keeps Their Buy Rating on Exact Sciences (EXAS)
01:13pm, Thursday, 19'th Mar 2020
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Exact Sciences (EXAS) today. The company's shares closed last Monday at $37.90, close to its
Oppenheimer Keeps Their Buy Rating on Exact Sciences (EXAS)
01:13pm, Thursday, 19'th Mar 2020
Oppenheimer analyst
Kevin DeGeeter
maintained a
Buy
rating on Exact Sciences (
EXAS
–
Research Report
) today. The company’s shares closed last Monday at $37.90, close to its 52-week low of $35.25
Vericel (VCEL) Gets a Buy Rating from Oppenheimer
01:52pm, Tuesday, 17'th Mar 2020
In a report released today, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Vericel (VCEL). The company's shares closed last Monday at $10.84,
Vericel (VCEL) Gets a Buy Rating from Oppenheimer
01:52pm, Tuesday, 17'th Mar 2020
In a report released today,
Kevin DeGeeter
from Oppenheimer maintained a
Buy
rating on Vericel (
VCEL
–
Research Report
). The company’s shares closed last Monday at $10.84, close to its 52-week l
Analysts Offer Insights on Healthcare Companies: PolarityTE (PTE) and Entasis Therapeutics Holdings (ETTX)
06:34pm, Thursday, 12'th Mar 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PolarityTE (PTE) and Entasis Therapeutics Holdings (ETTX)
Invitae (NVTA) Gets a Buy Rating from Oppenheimer
01:44am, Wednesday, 11'th Mar 2020
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Invitae (NVTA) yesterday and set a price target of $32.00. The company's shares closed last
Invitae (NVTA) Gets a Buy Rating from Oppenheimer
01:44am, Wednesday, 11'th Mar 2020
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Invitae (NVTA – Research Report) yesterday and set a price target
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results
10:55am, Wednesday, 04'th Mar 2020
SAN DIEGO, March 04, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a clinical-stage biotechnology company focused on the discovery, development and commercialization of.
